MTHFD1

Across TCGA pan-cancer cohorts, MTHFD1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MTHFD1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTHFD1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MTHFD1 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where MTHFD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTHFD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−0.597	<.001	12	view →
COAD	Male	All	+0.251	<.001	10	view →
LUAD	Male	III,IV	+0.351	<.001	9	view →
LSCC	Male	All	+0.349	<.001	8	view →
PDAC	Female	All	−0.390	<.001	4	view →
HNSC	All	All	−0.114	.006	4	view →
OV	All	All	+0.353	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MTHFD1–CCRCC

Open the CCRCC breakdown →